ID: MRFR/Pharma/1736-HCR | February 2021 | Region: Global | 85 pages
Market Synopsis of anti-asthma drugs market:
Asthma is a chronic lung disease characterized by hyper responsiveness of tracheobronchial smooth muscle to stimuli, resulting in narrowing and inflammation of air tubes, accompanied by increased secretion, swelling and build-up of tissue fluid. Symptoms include tight chest, wheezing, cough and may be limitation of activity due to difficulty in breathing.
Approximately, 300 million people suffer from asthma in 2015 and the figures are mounting which is blamed on increased pollution and unhealthy lifestyles. This has bloated the market to around USD 18.9 billion as of 2015 which is expected to reach USD 28.3 billion as of 2022, resulting in a CAGR of 5.94%. The factors favoring the growth of the market are growing awareness of the benefits of modern drug therapy, strong pipeline of anti-asthma drugs with some novel molecules, growth in patients due to increasing pollution and great potential of biologics which is anticipated to dominate the future market etc.
The constraining factors are loss of patents of leading brands, such as Advair and Symbicort, increasing fragmentation of markets and generic penetration. It is heartening to note that we anticipate that the growth factors will overwhelm the constraints and the market may take a strong growth due to commercialization of the biologics segment.
Study Objectives anti-asthma drugs market:
Anti-asthma drugs market, by Region 2015 & 2022 (USD million)
Key Players for anti-asthma drugs market:
GlaxoSmithKline plc., Merck & Co., Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries, Novartis International AG, Boehringer Ingelheim, Sunovion Pharmaceuticals Inc.
Anti-asthma drugs market has been segmented on the basis of by type, trigger, therapy, drug class and by route of administration.
Regional Analysis of anti-asthma drugs market:
Globally North America is the largest market for anti-asthma drugs. Europe is the second-largest market for anti-asthma drugs. The developing region especially Asia Pacific is accounting for major newer cases due to greater screening and better health care facilities distribution. However the developing regions market particularly Asia Pacific will be the fastest growing and will be the key to the future.
The report for Anti-Asthma Drugs Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
|Market Size||USD 28.3 Billion|
|Forecast Units||Value (USD Billion)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, trigger, therapy, drug class and by route of administration|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||GlaxoSmithKline plc., Merck & Co., Inc., AstraZeneca plc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries, Novartis International AG, Boehringer Ingelheim, Sunovion Pharmaceuticals Inc.|
|Key Market Opportunities||increasing pollution and great potential of biologics which is anticipated to dominate the future|
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Anti asthma drugs market is valued at USD 28.3 billion by 2022.
Anti asthma drugs market can expand at 5.94% CAGR from 2015 to 2022.
Anti asthma drugs market is driven by large number of asthma patients, advantages of modern drug therapy, and potential of biologics.
Patent expiry of blockbuster drugs is one of the biggest challenges faced by the global anti asthma drugs market.
The Americas can dominate the global anti asthma drugs market till 2022.
Novartis International AG, Teva Pharmaceutical Industries, AstraZeneca plc., F. Hoffmann-La Roche Ltd, Boehringer Ingelheim, GlaxoSmithKline plc., Merck & Co., Inc., and Sunovion Pharmaceuticals Inc. are notable players of the global anti asthma drugs market.
Table of Contents
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s five forces model
4.1.1 Bargaining Power of suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants
5 Global anti-asthma drugs market, by type
5.1.1 Allergic (extrinsic)
5.1.2 Non-allergic (intrinsic) asthma
6 Global anti-asthma drugs market, by trigger
6.1.1 Child-onset asthma
6.1.2 Adult-onset asthma
6.1.3 Exercise-induced asthma
6.1.4 Cough-induced asthma
6.1.5 Occupational asthma
6.1.6 Nocturnal asthma
6.1.7 Steroid-resistant asthma
7 Global anti-asthma drugs market, by drug class
7.1.1 Bronchodilators (beta agonists, anti-cholinergics, xanthines)
7.1.2 Leukotriene antagonists
7.1.3 Mast cell stabilizers
7.1.5 Monoclonal antibody
8 Global anti-asthma drugs market, by therapy
9 Global anti-asthma drugs market, by route of administration
10 Global anti-asthma drugs market, by Regions
10.1.1.1 North America
10.1.1.2 South America
10.1.2.6 Rest of Europe
10.1.3 Asia Pacific
10.1.3.4 Republic of Korea
10.1.3.5 Rest of Asia Pacific
10.1.4 Middle East & Africa
11 Company Landscape
11.1.1 Mergers Acquisitions
11.1.3 Release/New Product Launch
11.1.4 Other (Expansion, Updates, Partnership)
12 Company Profile
12.1 GlaxoSmithKline plc.
12.1.1 Company Overview
12.1.2 Product/Business Segment Overview
12.1.4 Key Developments
12.1.5 SWOT Analysis
12.2 Merck & Co., Inc.
12.2.2 Product/Business Segment Overview
12.2.4 Key Developments
12.2.5 SWOT Analysis
12.3 AstraZeneca plc.
12.3.2 Product/Business Segment Overview
12.3.4 Key Developments
12.3.5 SWOT Analysis
12.4 F. Hoffmann-La Roche Ltd
12.4.2 Product/Business Segment Overview
12.4.4 Key Developments
12.4.5 SWOT Analysis
12.5 Teva Pharmaceutical Industries
12.5.2 Product/Business Segment Overview
12.5.4 Key Developments
12.5.5 SWOT Analysis
12.6 Novartis International AG
12.6.2 Product/Business Segment Overview
12.6.4 Key Developments
12.6.5 SWOT Analysis
12.7 Boehringer Ingelheim
12.7.2 Product/Business Segment Overview
12.7.4 Key Developments
12.7.5 SWOT Analysis
12.8 Sunovion Pharmaceuticals Inc.
12.8.2 Product/Business Segment Overview
12.8.4 Key Developments
12.8.5 SWOT Analysis
List of Tables
TABLE 1 GLOBAL ANTI-ASTHMA DRUGS MARKET, 2020-2027 (USD MILLION)
TABLE 2 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TYPES, 2020-2027 (USD MILLION)
TABLE 3 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY TRIGGER, 2020-2027 (USD MILLION)
TABLE 4 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY DRUG CLASS, 2020-2027 (USD MILLION)
TABLE 5 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY THERAPY, 2020-2027 (USD MILLION)
TABLE 6 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
TABLE 7 GLOBAL ANTI-ASTHMA DRUGS MARKET, BY REGION, 2020-2027 (USD MILLION)